GMAB – Genmab A/S

GMAB — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

1.43

Margin Of Safety %

Put/Call OI Ratio

0.17

EPS Next Q Diff

0.17

EPS Last/This Y

-0.46

EPS This/Next Y

0.77

Price

26.91

Target Price

37.29

Analyst Recom

1.41

Performance Q

-9.09

Upside

73.0%

Beta

0.86

Ticker: GMAB

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-15	GMAB	29.3	1.02	0.19	20367
2026-04-20	GMAB	27.92	0.87	2.62	18816
2026-04-23	GMAB	26.98	0.36	0.06	37046
2026-04-24	GMAB	26.86	0.35	0.01	38036
2026-04-27	GMAB	26.65	0.35	0.01	38143
2026-04-28	GMAB	26.78	0.35	0.00	38532
2026-04-29	GMAB	26.09	0.20	0.00	58705
2026-04-30	GMAB	26.51	0.22	0.00	54904
2026-05-01	GMAB	26.45	0.20	0.06	60609
2026-05-04	GMAB	27.02	0.20	0.01	60502
2026-05-05	GMAB	27.52	0.19	0.02	60872
2026-05-06	GMAB	27.9	0.19	1.02	60881
2026-05-07	GMAB	27.06	0.20	0.63	61161
2026-05-08	GMAB	26.44	0.20	0.00	61155
2026-05-11	GMAB	26.19	0.18	0.56	65973
2026-05-12	GMAB	27.08	0.18	0.18	65992
2026-05-13	GMAB	26.56	0.18	0.74	66451
2026-05-14	GMAB	26.91	0.17	4.11	66250
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-15	GMAB	29.30	-62.9	-38.8	1.08
2026-04-16	GMAB	28.30	-62.9	-67.4	1.08
2026-04-17	GMAB	28.56	-62.9	-40.5	1.08
2026-04-20	GMAB	27.92	-62.9	-72.4	1.08
2026-04-21	GMAB	27.07	-62.9	-62.9	1.08
2026-04-22	GMAB	27.67	-62.9	-17.0	1.08
2026-04-23	GMAB	26.98	-60.7	-68.5	1.10
2026-04-24	GMAB	26.86	-60.7	-56.2	1.10
2026-04-27	GMAB	26.65	-60.7	-46.4	1.10
2026-04-28	GMAB	26.78	-47.5	-61.0	1.10
2026-04-30	GMAB	26.51	-47.5	-42.2	1.10
2026-05-01	GMAB	26.45	-42.6	-66.1	1.15
2026-05-04	GMAB	27.02	-42.6	-42.2	1.15
2026-05-05	GMAB	27.52	-42.6	-32.5	1.15
2026-05-06	GMAB	27.90	-42.6	-36.8	1.15
2026-05-07	GMAB	27.05	-42.6	-97.0	1.15
2026-05-08	GMAB	26.43	-42.6	-115.9	1.15
2026-05-11	GMAB	26.19	-44.0	60.3	1.01
2026-05-12	GMAB	27.08	-35.4	12.8	1.01
2026-05-13	GMAB	26.55	-35.4	-14.9	1.01
2026-05-14	GMAB	26.91	-	49.2	1.09
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-15	GMAB	0	0.20	1.39
2026-04-16	GMAB	0	0.20	1.39
2026-04-17	GMAB	0	0.20	1.39
2026-04-20	GMAB	0	0.13	1.39
2026-04-21	GMAB	0	0.13	1.39
2026-04-22	GMAB	0	0.13	1.39
2026-04-23	GMAB	0	0.13	1.39
2026-04-24	GMAB	0	0.13	1.39
2026-04-27	GMAB	0	0.12	1.29
2026-04-28	GMAB	0	0.12	1.29
2026-04-29	GMAB	0	0.12	1.33
2026-04-30	GMAB	0	0.12	1.33
2026-05-01	GMAB	0	0.12	1.33
2026-05-04	GMAB	0	0.09	1.33
2026-05-05	GMAB	0	0.09	1.33
2026-05-06	GMAB	0	0.09	1.33
2026-05-07	GMAB	0	0.09	1.33
2026-05-08	GMAB	0	0.09	1.33
2026-05-11	GMAB	0	0.09	1.33
2026-05-12	GMAB	0	0.09	1.43
2026-05-13	GMAB	0	0.09	1.43
2026-05-14	GMAB	0	0.09	1.43
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

0.15

Avg. EPS Est. Current Quarter

0.3

Avg. EPS Est. Next Quarter

0.32

Insider Transactions

Institutional Transactions

0.09

Beta

0.86

Average Sales Estimate Current Quarter

6926

Average Sales Estimate Next Quarter

7291

Fair Value

29.62

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

45.2

Max Drawdown 5-Year %

-63.1

Target Price

37.29

P/E

20.29

Forward P/E

15.95

PEG

0.86

P/S

4.09

P/B

2.91

P/Free Cash Flow

18.28

EPS

1.33

Average EPS Est. Cur. Y

1.09

EPS Next Y. (Est.)

1.87

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

21.06

Relative Volume

0.85

Return on Equity vs Sector %

-12.5

Return on Equity vs Industry %

3.1

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.08

EBIT Estimation

49.2

◆ GMAB Healthcare

$26.90

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

15/25

Volume

7/15

Valuation

18/20

TP/AR

2/10

Options

6/10

RSI

48.2

Range 1M

38.3%

Sup Dist

2.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

13/30

Estimates

6/20

Inst/Vol

3/15

Options

7/10

EPS Yr

-25%

EPS NY

46.3%

52W%

47.1%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟢 BUY +82.4% upside

Quality

15/30

Valuation

22/30

Growth

9/25

Stability

5/10

LT Trend

0/5

Upside

+82.4%

Quality

MoS

10%

Genmab A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 3088

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

GMAB

Latest News

—

Caricamento notizie per GMAB…

stock quote shares GMAB – Genmab A/S Stock Price stock today

news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch GMAB – Genmab A/S yahoo finance google finance

stock history GMAB – Genmab A/S invest stock market

stock prices GMAB premarket after hours

ticker GMAB fair value insiders trading

NVO – Novo Nordisk A/S

NVO — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.42

Margin Of Safety %

-16

Put/Call OI Ratio

0.69

EPS Next Q Diff

3.69

EPS Last/This Y

19.77

EPS This/Next Y

-1.79

Price

45.79

Target Price

48.91

Analyst Recom

2.5

Performance Q

-6.42

Upside

20.9%

Beta

0.8

Ticker: NVO

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-15	NVO	40.82	0.69	0.58	1519932
2026-04-20	NVO	40.46	0.71	0.63	1363091
2026-04-23	NVO	38.5	0.71	0.47	1443266
2026-04-24	NVO	41.15	0.71	0.27	1458931
2026-04-27	NVO	41.18	0.68	0.29	1435545
2026-04-28	NVO	41.17	0.67	0.21	1475040
2026-04-29	NVO	40.28	0.67	0.54	1488866
2026-04-30	NVO	42.2	0.68	0.30	1521125
2026-05-01	NVO	43.88	0.68	0.44	1539834
2026-05-04	NVO	44.4	0.69	0.29	1515880
2026-05-05	NVO	44.9	0.69	0.50	1537073
2026-05-06	NVO	45.74	0.68	0.39	1584436
2026-05-07	NVO	45.81	0.68	0.42	1592900
2026-05-08	NVO	46.09	0.68	0.28	1603572
2026-05-11	NVO	46.4	0.69	0.38	1501570
2026-05-12	NVO	46.97	0.69	0.34	1510947
2026-05-13	NVO	47.08	0.69	0.52	1519844
2026-05-14	NVO	45.81	0.69	0.28	1531138
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-15	NVO	40.81	4.6	-803.4	21.44
2026-04-16	NVO	40.92	4.6	-1169.2	21.44
2026-04-17	NVO	40.50	6.6	-1725.0	21.44
2026-04-20	NVO	40.47	6.6	-1955.0	21.44
2026-04-21	NVO	39.42	6.6	-2083.0	21.87
2026-04-22	NVO	39.15	6.6	-1281.1	21.87
2026-04-23	NVO	38.51	6.6	-1706.9	21.98
2026-04-24	NVO	41.17	6.6	-327.7	21.98
2026-04-27	NVO	41.19	6.6	-1280.7	21.98
2026-04-28	NVO	41.16	6.6	-1799.2	21.98
2026-04-30	NVO	42.20	6.6	-816.1	21.98
2026-05-01	NVO	43.88	6.6	-1257.0	21.98
2026-05-04	NVO	44.40	6.6	-1418.3	21.98
2026-05-05	NVO	44.90	6.6	-1533.3	21.98
2026-05-06	NVO	45.75	6.6	-1402.4	21.98
2026-05-07	NVO	45.78	6.6	-14501.7	21.98
2026-05-08	NVO	46.08	6.6	-14310.4	21.98
2026-05-11	NVO	46.40	-12.9	-13530.0	26.55
2026-05-12	NVO	46.98	-12.9	-13986.1	23.37
2026-05-13	NVO	47.08	-12.9	-13848.8	23.37
2026-05-14	NVO	45.79	-12.9	-14208.4	23.37
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-15	NVO	0.00	0.16	0.59
2026-04-16	NVO	0.00	0.16	0.59
2026-04-17	NVO	0.00	0.16	0.59
2026-04-20	NVO	0.00	0.06	0.59
2026-04-21	NVO	0.00	0.06	0.59
2026-04-22	NVO	0.00	0.06	0.59
2026-04-23	NVO	0.00	0.06	0.59
2026-04-24	NVO	0	0.06	0.59
2026-04-27	NVO	0	-0.15	0.51
2026-04-28	NVO	0	-0.15	0.51
2026-04-29	NVO	0	-0.15	0.51
2026-04-30	NVO	0	-0.15	0.51
2026-05-01	NVO	0	-0.15	0.51
2026-05-04	NVO	0	-0.36	0.51
2026-05-05	NVO	0	-0.36	0.51
2026-05-06	NVO	0	-0.36	0.51
2026-05-07	NVO	0	-0.36	0.51
2026-05-08	NVO	0	-0.36	0.51
2026-05-11	NVO	0	-0.56	0
2026-05-12	NVO	0	-0.56	0.42
2026-05-13	NVO	0	-0.56	0.42
2026-05-14	NVO	0	-0.56	0.42
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

1.04

Avg. EPS Est. Current Quarter

5.19

Avg. EPS Est. Next Quarter

4.73

Insider Transactions

Institutional Transactions

-0.56

Beta

0.8

Average Sales Estimate Current Quarter

72241

Average Sales Estimate Next Quarter

71299

Fair Value

38.65

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

69.1

Max Drawdown 5-Year %

-74.7

Target Price

48.91

P/E

10.75

Forward P/E

13.73

PEG

52.79

P/S

3.03

P/B

6.5

P/Free Cash Flow

24.05

EPS

4.26

Average EPS Est. Cur. Y

23.37

EPS Next Y. (Est.)

21.58

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

37.23

Relative Volume

0.62

Return on Equity vs Sector %

33.2

Return on Equity vs Industry %

EPS 1 7Days Diff

1.4

EPS 1 30Days Diff

1.91

EBIT Estimation

-14208.4

◆ NVO Healthcare

$45.79

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

6/20

Pullback

0/25

Volume

9/15

Valuation

11/20

TP/AR

1/10

Options

7/10

RSI

66.4

Range 1M

79.8%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

13/30

Estimates

6/20

Inst/Vol

0/15

Options

6/10

EPS Yr

-8.6%

EPS NY

0.3%

52W%

23.1%

💎

Long-Term Value

Quality companies, undervalued

WATCH

🟢 BUY +253% upside

Quality

30/30

Valuation

19/30

Growth

11/25

Stability

3/10

LT Trend

4/5

Upside

+253%

Quality

MoS

-16%

Novo Nordisk A/S

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 67900

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

NVO

Latest News

—

Caricamento notizie per NVO…

stock quote shares NVO – Novo Nordisk A/S Stock Price stock today

news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch NVO – Novo Nordisk A/S yahoo finance google finance

stock history NVO – Novo Nordisk A/S invest stock market

stock prices NVO premarket after hours

ticker NVO fair value insiders trading

ASND – Ascendis Pharma A/S

ASND — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

4.6

Margin Of Safety %

-63

Put/Call OI Ratio

0.49

EPS Next Q Diff

EPS Last/This Y

14.63

EPS This/Next Y

-0.91

Price

245.38

Target Price

293.25

Analyst Recom

1.06

Performance Q

12.56

Upside

-53.0%

Beta

0.41

Ticker: ASND

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-15	ASND	241.51	0.16	4.88	20470
2026-04-16	ASND	242.69	0.17	0.01	20719
2026-04-17	ASND	244.61	0.17	0.17	20410
2026-04-20	ASND	245.6	0.34	0.04	8466
2026-04-21	ASND	240.68	0.34	0.02	8594
2026-04-22	ASND	231.03	0.34	0.69	8625
2026-04-23	ASND	224.83	0.36	1.37	9225
2026-04-24	ASND	229.33	0.38	0.55	9432
2026-04-27	ASND	226.93	0.39	0.04	9718
2026-04-28	ASND	222.05	0.37	0.04	10156
2026-04-29	ASND	220.13	0.33	0.07	11342
2026-04-30	ASND	229.26	0.32	0.72	11490
2026-05-01	ASND	220.77	0.35	11.73	11952
2026-05-04	ASND	228.53	0.38	0.00	12287
2026-05-05	ASND	225.22	0.34	1.74	11682
2026-05-06	ASND	235.86	0.34	0.24	11683
2026-05-07	ASND	246.06	0.37	0.19	11379
2026-05-08	ASND	238.44	0.46	0.55	10960
2026-05-11	ASND	238.46	0.49	0.44	11029
2026-05-12	ASND	237.64	0.49	0.91	11075
2026-05-13	ASND	243.7	0.49	1.22	11045
2026-05-14	ASND	245.59	0.49	0.46	11104
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-15	ASND	241.68	124.8	394.3	4.42
2026-04-16	ASND	242.87	124.8	395.5	4.42
2026-04-17	ASND	244.57	124.8	397.1	4.42
2026-04-20	ASND	245.34	121.7	397.9	4.42
2026-04-21	ASND	240.40	121.7	393.1	4.42
2026-04-22	ASND	231.27	121.7	388.7	4.42
2026-04-23	ASND	224.99	121.7	382.5	4.42
2026-04-24	ASND	229.24	-	386.7	4.67
2026-04-27	ASND	226.78	-	384.2	4.67
2026-04-28	ASND	222.05	-	379.5	2.82
2026-04-30	ASND	229.34	-	386.8	2.82
2026-05-01	ASND	220.86	-	378.4	2.82
2026-05-04	ASND	228.52	-	386.0	2.82
2026-05-05	ASND	225.35	-	382.8	2.82
2026-05-06	ASND	235.89	-	396.5	2.82
2026-05-07	ASND	246.17	-	-	2.82
2026-05-08	ASND	238.51	-	-	2.82
2026-05-11	ASND	238.34	-	-	3.63
2026-05-12	ASND	237.75	-	-	3.44
2026-05-13	ASND	243.65	-	-	10.21
2026-05-14	ASND	245.38	-	-	10.21
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-15	ASND	0.00	1.41	6.08
2026-04-16	ASND	0.00	1.41	6.08
2026-04-17	ASND	0.00	1.41	6.08
2026-04-20	ASND	0.00	1.66	6.08
2026-04-21	ASND	0.00	1.66	6.08
2026-04-22	ASND	0.00	1.66	6.08
2026-04-23	ASND	0.00	1.66	6.08
2026-04-24	ASND	0.00	1.66	6.08
2026-04-27	ASND	0.00	1.93	6.01
2026-04-28	ASND	0.00	1.93	6.01
2026-04-29	ASND	0.00	1.93	6.01
2026-04-30	ASND	0.00	1.93	6.01
2026-05-01	ASND	0.00	1.93	6.01
2026-05-04	ASND	0.00	-50.00	6.01
2026-05-05	ASND	0.00	-50.00	6.01
2026-05-06	ASND	0.00	-50.00	6.01
2026-05-07	ASND	0.00	-50.00	6.01
2026-05-08	ASND	0.00	-50.00	6.01
2026-05-11	ASND	0.00	-47.30	0
2026-05-12	ASND	0.00	-47.30	4.60
2026-05-13	ASND	-3.33	-47.30	4.60
2026-05-14	ASND	-3.33	-47.30	4.60
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

1.37

Avg. EPS Est. Next Quarter

1.21

Insider Transactions

-3.33

Institutional Transactions

-47.3

Beta

0.41

Average Sales Estimate Current Quarter

339

Average Sales Estimate Next Quarter

358

Fair Value

91.13

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

293.25

P/E

27.67

Forward P/E

22.51

PEG

P/S

15.17

P/B

27.12

P/Free Cash Flow

301.51

EPS

8.87

Average EPS Est. Cur. Y

10.21

EPS Next Y. (Est.)

9.3

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

57.88

Relative Volume

0.4

Return on Equity vs Sector %

74.7

Return on Equity vs Industry %

90.2

EPS 1 7Days Diff

7.4

EPS 1 30Days Diff

10.21

EBIT Estimation

◆ ASND Healthcare

$245.49

📉

Swing / Pullback

Buy the dip on strong trends

WATCH

Trend

20/20

Pullback

8/25

Volume

8/15

Valuation

7/20

TP/AR

4/10

Options

8/10

RSI

58.6

Range 1M

85.3%

Sup Dist

3.3%

🚀

Momentum Growth

Ride accelerating trends

WATCH

Momentum

19/25

Growth

23/30

Estimates

5/20

Inst/Vol

3/15

Options

7/10

EPS Yr

423.5%

EPS NY

-23.5%

52W%

94.5%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🔴 SELL -40.4% upside

Quality

26/30

Valuation

0/30

Growth

16/25

Stability

3/10

LT Trend

4/5

Upside

-40.4%

Quality

MoS

-63%

Ascendis Pharma A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 1189

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

ASND

Latest News

—

Caricamento notizie per ASND…

stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today

news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance

stock history ASND – Ascendis Pharma A/S invest stock market

stock prices ASND premarket after hours

ticker ASND fair value insiders trading

GMAB – Genmab A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: GMAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

NVO – Novo Nordisk A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: NVO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y